anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The Wnt signaling pathways are involved in embryo development as well as in M tumorigenesis. Dishevelled (Dv1) tra®&#39;duces Wnt signals from the receptor Frizzled (Fz) to downstream components in canonical and non-canonical Wnt signaling pathways, and the Dv1. PDZ domain plays an essential role in both pathways, and the Dv1 PDZ .domain binds directly to Fz receptors. In the present invention using NMR-assisted virtual ligand screening, several compounds were identified and were found to bind to the Dv1 PDZ domain. Molecular dynamics simulation was used to analyze the binding between the PDZ domain and these compounds in detail. These compounds provide a basis for rational design of high-affinity inhibitors of the PDZ domain, which can block Wnt signaling by interrupting the Fz-Dv1 interaction.
1488988 Stabilizing agent for enzymes BOEHRINGER MANNHEIM GmbH 25 Nov 1975 48363/75 Heading C3H A stabilizing agent for labile enzymes comprises a protein fraction which is the precipitate obtained by the action of trichloroacetic acid (5-20 wt. per cent/vol.) on the clear extract obtained by the extraction of digested yeast or yeast waste with water at a temperature of from 80‹ to 100‹ C. and separation of the precipitate. The precipitate may be further purified by dissolution in water at substantially neutral pH, subjected to ethanol fraction precipitation wherein the precipitate obtained with from 45 to 90% by volume of ethanol, based on the volume of solution is recovered, taken up in a buffer of substantially neutral pH, dialysed against said buffer and, optionally, subjected to chromatographic purification. The stabilizing agent is preferably in the form of a solution of pH above 5 with a protein content of from 5 to 200 mg./ml. In the examples, the enzymes stabilized are glycerokinase (from Candida mycoderma), glucose 6-phosphate dehydrogenase, glycerokinase/ Aspergillus niger composition, maleate dehydrogenase (from cardiac muscle), glucose dehydrogenase (from Bacillus subtilis), aldehyde dehydrogenase (from baker&#39;s yeast) and glucose oxidase (from mould fungus).
Cancer detection reagents have been identified through comparison of cancer mRNAs with the transcriptome of healthy cells. These cancer detection reagents may be used for a variety of purposes including diagnostics and targeted destruction of cancer cells. In diagnostic applications, peripheral blood or other tissue samples from a subject may be analyzed to generate a cancer profile for that subject. That profile may then be used to guide cancer treatment with known agents. It may also be used to generate agents capable of killing the subject&#39;s cancer cells in a targeted manner. These agents may include antibodies and siRNA, RNAi, or antisense RNA.
The invention concerns nucleotides vaccines encoding influenza proteins with few or no glycosylation sites. Since these first introductions of pandemic influenzas the viruses have drifted, accumulating mutations at antigenic sites, but also the N-glycosylation pattern has changed during the drifted years, accumulating N-linked glycosylation sequons that help mask the antigenic sites for recognition by the host immune system. These &#34;naked&#34; initial haemagglutinins induce a broad cross reactivity against widely drifted influenza subtypes. The origin of the DNA or RNA can be both pandemic influenza strains, which codes for proteins which have a naturally low content of glycosylation sites and/or DNA or RNA from non-pandemic influenza strains where the nucletides have been mutated or changed so it encodes for proteins with less or no glycosylation sites. The invention also discloses DNA or RNA encoding the haemagglutinin (HA) from pandemic influenza A, e.g. the 1918 H1N1 and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus,, optionally with the Neuraminidase (NA) and/or matrix protein (M) and/or the nucleoprotein (NP) from these pandemic influenza virus included, mixed together with DNA or RNA from non-pandemic influenza A as a vaccine against present day and future influenza A viruses.
A computer-based method aids comparison of competitive performance of a first provider of services with other providers of the services, where the services are provided to a mix of customers belonging to different classes and the performance in providing the services is different for customers belonging to different classes. Data representing the first provider&#39;s competitive performance in providing various services to its customers is stored. Also stored is mix data representing the mix of its customers to which the services are provided. Similar data is stored representing each of the other providers&#39; competitive performance in providing various services to its customers. The data of the other providers is adjusted in accordance with the mix data of the first provider. The unadjusted data of the first provider is visually provided together with the adjusted data of the other providers. Other aspects include automatically generating a printed report of information comparing performance of a first provider of services with performances of other providers of the services; and more broadly generating a report of an analysis of data.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cosmetic which has effects for correcting skin defects such as color irregularity, e.g. blotches, freckles, or dullness, or skin unevenness, e.g. skin pores or wrinkles, gives the skin the finish with natural transparent feeling, coloring, and gloss, and exhibits good extensibility and good feel to the touch; and to provide a powder compounded into the cosmetic.  &lt;P&gt;SOLUTION: There is provided interference-color flaky talc of which the surface is covered with at least one oxide selected from among titanium oxide, silicon oxide, aluminum oxide, zinc oxide, and zirconium oxide and which has an interference color and a particle size (measured by a laser method) of 1-80 μm. The cosmetic is prepared by compounding the interference-color flaky talc.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of sexual dysfunction. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid &#34;stick,&#34; etc., that can be rubbed or sprayed onto the skin, e.g., onto the penis, vulva, or other suitable portion of the skin. The composition can also be applied to a mucosal surface in some instances. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
PROBLEM TO BE SOLVED: To obtain a detergent compsn. which is excellent in lathering capability and detergency, is hardly skin-irritating, and has a suitable viscosity by compounding a hydroxyether carboxylic acid type anionic surfactant and a fatty acid amide propylbetaine, each in a specified amt. SOLUTION: 1-20 wt.% at least one hydroxyether carboxylic acid type anionic surfactant of formula I and 1-20 wt.% at least one fatty acid amide propylbetaine are compounded. In formula I, R&lt;1&gt; is a hydrocarbon group having on average 8-22 carbon atoms; and M&lt;1&gt; is an alkali or alkaline earth metal, ammonium, or an org. amine. Sodium dodecane-1,2-diolacetic acid ether is pref. as the compd. of formula I. Pref., the fatty acid amide propylbetaine is a long- chain fatty acid amide propylbetaine of formula II and mainly comprises a compd. of which the average number of carbon atoms of R&lt;2&gt; CO is 14. In formula II, R&lt;2&gt; CO is a residue of a fatty acid of which the average number of carbon atoms is 10-22.
A user interface for a medical instrument such as a dialysis machine is described which uses both a touch screen and at least one hard key off of the touch screen to effectuate a change in a parameter associated with the operation of the machine or the treatment session. The user interface is connected to a central computer control system having a host microprocessor and a backup safety microprocessor. The hard key is directly wired to the safety microprocessor. After the user selects a new parametric value on the touch screen, the user presses a hard key. The host and safety microprocessors implement a verification routine to insure that the entered parameter is appropriate for the patient&#39;s treatment and the display on the touch screen. If the verification procedure ends in a positive result, the user is prompted to presses a second hard key to confirm the change, causing an additional verification check to be performed. If the additional verification check is successful, the parametric value is entered into a memory (such as a hard disk) storing instructions for operation of the medical instrument.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a light irradiation apparatus for rheumatism treatment which is easy to handle without taking the risk of side reaction by a biological formulation.  &lt;P&gt;SOLUTION: Joint-related cells centering on macrophage 3 are irradiated with treatment light 12 from a light emitting element and at least the production of IL-1β(8) and IL-6(10) produced from the joint-related cells is suppressed. By that, by suppressing the surplus production of TNF-α(9) and IL-1β(8) happening inside the joint of a patient suffering from rheumatism by irradiating a joint part with light, inflammation is suppressed. That is, since the production of TNT-α(9) of the whole body is not suppressed, various kinds of side reaction due to lack of TNF-α(9) observed in infliximab treatment do not occur. In the meantime, in the aspect of treatment costs, an expensive chemical is not used, a light source not to be reduced from use is repeatedly used, and thus an inexpensive treatment method is provided.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
FIELD: medicine, microbiology. SUBSTANCE: method deals with preparing immune sera. The method deals with applying microbes of B.mallei C-5 strain as an industrial one with the help of which, after adding phenol and heating, one should prepare a corpuscular antigen to be used for intravenous cyclic immunization of rabbits according to a certain scheme. Sera are obtained on the 10th d after immunization and lyophilized. The method provides to obtain a highly active and stable polyvalent glanderous serum useful to control the quality of erythrocytic antigenic glanderous diagnostic kit and agglutinogenic properties of glanderous agent&#39;s cultures. EFFECT: higher efficiency. 4 tbl
The food additive is used to reduce the high cholesterol levels, and it has at the same time an antioxidant effect, improves the working capacity, restores the leucocytes and raises the immunity after irradiation. It represents various functional drinks based on young ecological red wines, solutions, granules, hard or soft capsules and tablets, including covered tablets. The additive contains in mg: a combination of antocianes based on young ecological red wines û 120 to 250 and/or grape seed proanthocyanidins û 50 to 100 and/or brewer&#39;s yeast washed four times with water, filtered and lyophilized û 80 to 220 for one dose and/or vitamins. Subsidiary pharmaceutical substances may be added, if necessary. The additive can be in the form of enterosolvent powders. The vitamins are C and/or E and/or B complex.
PROBLEM TO BE SOLVED: To provide the subject composition excellent in dandruff proof action and free from discoloration in long time storage containing selenium disulfide and a zinc salt of an inorganic acid or an organic carboxylic acid as a stabilizer in an aqueous medium. SOLUTION: This composition contains (A) selenium disulfide in a mixture with (B) a zinc salt of an inorganic acid or an organic carboxylic acid (preferably zinc chloride, zinc lactate or zinc citrate) in an aqueous medium. Preferably (A) is a powder having particle size &lt;2.5mm. The preferable amount of ingredient (A) is 0.25-2wt.% and ingredient (B) is 0.1-3wt.% based on the total weight of the composition. The weight ratio of ingredient (B) to ingredient (A) is preferably 0.2-2. The composition is preferably used as shampoo and in this case 0.05-30wt.% of a surfactant is preferably formulated. Water or a mixture of water and ethanol is preferred as an aqueous medium.
PCT No. PCT/FR89/00094 Sec. 371 Date Sep. 7, 1990 Sec. 102(e) Date Sep. 7, 1990 PCT Filed Mar. 8, 1989 PCT Pub. No. WO89/08657 PCT Pub. Date Sep. 21, 1989.The invention relates to the preparation of complexes of 99m-technetium, 186-rhenium or 188-rhenium usable as radiopharmaceutical products. For this preparation, an oxidized compound of 99mTc, 186Re or 188Re, e.g. an alkali metal or ammonium perrhenate or pertechnetate, is reacted with a first ligand chosen from the group of substituted or unsubstituted, aliphatic and aromatic phosphenes and polyphosphenes and a second nitrogenous ligand constituted by an ammonium nitride or a pharmaceutically acceptable metal or by a nitrogenous compound having a &gt;N-N&lt; unit, such as hydrazine, a hydrazine derivative, dithiocarbazic acid and dithiocarbazic acid derivatives. The product obtained can be used as it is as a radiopharmaceutical product or can serve as an intermediate for the preparation of other radiopharmaceutical products by exchange reaction with a third ligand, a monoclonal antibody or an antibody fragment.
PURPOSE: To obtain a composition for oral cavities, high in a chemical cleaning effect, and capable being suitably used for removing tooth stains adhered and deposited to the surfaces of the teeth. CONSTITUTION: 0.2-15wt.% of an orthophosphate salt (e.g. disodium biphosphate) is added to a composition for oral cavities containing an alkyl sulfate salt (e.g. sodium laurylsulfate) in an amount of 0.01-5wt.% based on the whole composition, and a water-soluble polyphosphate salt of formula: Mn+2 Pn O3n+1 (M is Na, K; n&gt;=2) and formula: (MPO3 )m (m&gt;=3) in an amount of &gt;=1wt.%. The orthophosphate salt is compounded in an amount of &gt;=0.2 times weight, preferably 0.2-1.1 times weight that of the polyphosphate salt. A surfactant selected from an N-acylamino acid, its salt and a polyoxyethylenealkyl ether sulfate salt is preferably further compounded in an amount of 0.01-7wt.%. The composition for the oral cavities is further compounded with conventional components, adjusted to a pH of 6-10, and subsequently processed into dentifrice such as tooth pastes, mouth washes, etc.  The composition can remove stains on teeth, such as stains, plaques, cigarette tars, etc., by the chemical action.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a means solving coating film unevenness in a two-layer type algae pack optionally containing an oily phase.  &lt;P&gt;SOLUTION: A pack cosmetic designed to form a coating film by hardening alginic acid and/or a water-soluble salt thereof with alkaline earth metal ion is provided. The pack cosmetic is such one that the alginic acid and/or the water-soluble salt thereof is contained in an emulsified composition and the composition is mixed with a composition containing a sparingly water-soluble salt of the alkaline earth metal when to be used. Preferably, this pack cosmetic contains a coloring matter as the indicator for mixing degree. The sparingly water-soluble salt of the alkaline earth metal is preferably e.g. calcium carbonate, calcium sulfate, magnesium carbonate, magnesium sulfate, barium carbonate, barium sulfate.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
PURPOSE: To obtain a shampoo compsn. for hair conditioning having product stability for a long period of time and superior cleaning characteristics and imparting unexpectedly superior general conditioning properties to human&#39;s hair, especially superior suitability to wet- and dry-stage combing. CONSTITUTION: This shampoo compsn. contains an anionic surfactant, a water- soluble cationic conditioning compd. which is preferably a polymer, a water- insoluble liq. conditioning compd. having about &lt;20 cP viscosity at 25 deg.C, a specific gravity of &lt;1.0, preferably about &lt;0.95 and a refractive index of at least about 1.4 at 25 deg.C and a suspending agent for the water-insoluble conditioning compd. in a proper vehicle. The water-insoluble conditioning agent is effectively deposited on hair so as to remarkably improve suitability to dry-stage combing and lubricity that are not practically improved by the water-soluble cationic conditioning agent.
FIELD: medicine, cosmetics and sports. SUBSTANCE: plaster has supporting layer, plaster mass applied to supporting layer and protective layer. Supporting layer is manufactured from polymer material and provided with cover preventing volatile compounds of plaster mass from penetration into environment in the process of applying plaster to individual&#39;s skin. Plaster mass is composed of polymer layer within which fir oil is uniformly distributed. Fir oil is used as active substance. Plaster may be used for acting upon skin and subcutaneous tissues (endermic and adermic) as analgesic possessing heating effect. EFFECT: wider range of use and effectiveness and simplified structure. 1 ex
- 27 -An object of the present invention is to provide a lipase activity inhibitor that shows high inhibitory activity against pancreatic lipase to suppress the absorption of meal-derived fat and/or which contributes to suppressing and preventing obesity, as well as a food or beverage that has such lipase activity inhibitor incorporated therein. Another object of the invention is to provide a lipase inhibitor of tea origin that suits most consumers&#39; taste and which will not impair the flavor of the food or beverage when incorporated therein. Still another object of the invention is to provide a process for producing said lipase inhibitors. Further object of the invention is to provide antioxidants. To attain these objects, epigallocatechin diners (oolong homobisflavans) or trimers are incorporated in foods or beverages. As a result, the absorption of meal-derived fat can be suppressed and, in addition, antioxidation effect is obtained. The compounds of the invention can be produced by reacting epigallocatechin gallate with formaldehyde in the presence of an acid.
PURPOSE:To provide an antimicrobial agent exhibiting high antimicrobial, antifungal and deodorant effects when mixed with or coated on resins, coatings, fibers, cosmetics, etc., and comprising fine particles dispersed in a medium, the fine particles comprising an antimicrobial metal component having a specific bonding force index and an inorganic oxide excluding the component. CONSTITUTION:A colloidal solution is characterized in that fine particles comprising an antimicrobial metal component and an inorganic oxide excluding the component are dispersed therein. The antimicrobial metal component is mixed or reacted with the inorganic oxide to form colloidal particles in the form of a mixture or compound, or the antimicrobial metal component is bonded to the surfaces of the inorganic oxide colloidal particles. The antimicrobial metal component has a bonding force index of &lt;=1.0Xl/10&lt;3&gt;, the bonding force index being expressed by a B/A wherein A is the weight of the antimicrobial metal component in the colloidal solution; B is the weight of the antimicrobial metal component separated by subjecting the colloidal solution to an ultracentrifugal treatment. The antimicrobial metal component is preferably silver, copper, zinc, tin, lead, bismuth, cadmium, chromium, mercury, etc., more preferably silver copper or zinc. The inorganic oxide includes SiO2, tiO2, SiO2.Al2O3.
&lt;P&gt;PROBLEM TO BE SOLVED: To support the handling of an article.  &lt;P&gt;SOLUTION: An electronic circuit chip 2 is installed on an ingested matter 1, and an ID code is read from the electronic circuit chip 2 by an ID reader 3. A user terminal 4 notifies an ID administration server 5 of the ID code to acquire the address of an attribute information administration server 6 administrating the attribute of the ingested matter 1. The user terminal 4 notifies the destination attribute information administration server 6 for the acquired address of the ID code. Then, the attribute information administration server 6 specifies the attribute information of the ingested matter 1 and notifies an ingestion administration support server 7. The ingestion administration support server 7 prepares a message for the ingestion action of the ingested matter 1 by using the ingestion action history of a user and the attribute information on the ingested matter 1 self-controlled by the user, and notifies the user terminal 4 of the message.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an X-ray contrast medium which is highly safe and has a proper half-life, and to provide a method for producing the same.  &lt;P&gt;SOLUTION: This contrast medium for X-ray examination is characterized by containing liposomes containing a water-soluble and nonionic iodine compound and having a blood retention time of 0.25 to 4 hours as a half-life. The above-mentioned liposome is preferably a single membrane liposome. The central particle diameter of the liposome is preferably 50 to 500 nm. The liposome is especially preferably a PEG-reacted liposome containing the PEG having oxyethylene units of 10 to 3,500 in an amount of 0.1 to 30 mass % based on the lipid constituting the liposome.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE: An aqueous insulin preparation comprising human insulin, an analog or derivative thereof is provided which improves chemical stability thereof. CONSTITUTION: An insulin preparation having superior chemical stability is prepared in the presence of glycerol and/or mannitol, and low concentration in particular, 5-100 mM, preferably, 5-40 mM of halogenide. Especially, in low concentration of halogenide, its physical stability can&#39;t not be denatured. Wherein, halogenide is preferably, alkaly, or alkalyto compounds and more preferably, chlorides such as sodium chloride. The concentration of glycerol and/or mannitol is 100-250 mM, more desirably, 140-250 mM and most desirably, 160-200 mM. Optionally, the preparation comprises phosphoric acid and citric acid and formulated for non oral administration.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide sustained release fine particles of a fat-soluble medicine having high enclosure ratio of the fat-soluble medicine, scarcely causing initial burst and not using harmful additive and to provide a method for producing the fine particles.  &lt;P&gt;SOLUTION: The fat-soluble medicine and a biodegradable polymer are dissolved in a fat-soluble vitamin and the solution is jetted into a lecithin thin film and water or a physiological saline is added thereto and then, the fat-soluble vitamin is dispersed into the interior of the thin film by ultrasonic irradiation or homogenizing operation. As a result, globular fine particles in which the fat-soluble vitamin in which the fat-soluble medicine and the biodegradable polymer are dissolved are sealed into the interior of the lecithin thin film are formed. Since strong interaction acts between the lecithin and the fat-soluble vitamin and between the fat-soluble vitamin and the biodegradable polymer, the fat-soluble medicine can be absorbed into the outer surface of fine particles and the enclosure ratio and introduction ratio of the fat-soluble medicine are high. In the production method, stability of the fine particles is also high and the included medicine is scarcely transferred into the blood.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI